Edinburgh Molecular Imaging ^Companies

Edinburgh Molecular Imaging is a Scottish organization founded in 2014. Originally focused on developing fluorescent optical imaging agents for cancer detection and surgical guidance, the company has now transformed into therapeutics. Their main goal is to develop systemic radiotheragnostic pairs targeting c-Met, with the potential to treat various types of cancer. The company has achieved proof of concept in 16 patients and has started clinical development. With a team of experts in imaging agent discovery, clinical development, and commercialization, Edinburgh Molecular Imaging is dedicated to advancing cancer treatment and improving patient outcomes.